Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.

导出原文传递

翻译打印收藏纠错

作者： Shuiling,Jin ^[1] ; Ruihua,Zhao ^[1] ; Chuang,Zhou ^[2] ; Qian,Zhong ^[1] ; Jianxiang,Shi ^[3] ; Chang,Su ^[1] ; Qinglong,Li ^[4] ; Xiaoxing,Su ^[5] ; Huabin,Chi ^[5] ; Xu,Lu ^[2] ; Guozhong,Jiang ^[6] ; Renyin,Chen ^[6] ; Jinming,Han ^[1] ; Miao,Jiang ^[1] ; Shishi,Qiao ^[2] ; Jingjing,Liu ^[7] ; Min,Song ^[1] ; Lijie,Song ^[1] ; Yabing,Du ^[1] ; Zhiwei,Chang ^[1] ; Meng,Wang ^[4] ; Meilian,Dong ^[8] ; Yali,Zhong ^[1] ; Pu,Yu ^[1] ; Xiaojian,Zhang ^[9] ; Hong,Zong ^[1]

作者单位： Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ^[1] Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ^[2] BGI College & Henan Institute of Medical and Pharmaceutical Sciences in Academy of Medical Science, Zhengzhou University, Zhengzhou, China. ^[3] Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ^[4] Bioinformatics, Berry Oncology Co. Ltd, Fujian, China. ^[5] Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ^[6] Department of MR Imaging, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ^[7] Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ^[8] Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ^[9]

关键词 advanced biliary tract cancers anlotinib phase II study second line sintilimab

主题词人类(Humans);可行性研究(Feasibility Studies);胆管肿瘤(Bile Duct Neoplasms);胆道肿瘤(Biliary Tract Neoplasms);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols)

DOI 10.1002/ijc.34372

PMID 36444498

发布时间 2023-03-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交